These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21857299)

  • 21. Leveraging the private health sector to enhance HIV service delivery in lower-income countries.
    Rao P; Gabre-Kidan T; Mubangizi DB; Sulzbach S
    J Acquir Immune Defic Syndr; 2011 Aug; 57 Suppl 2():S116-9. PubMed ID: 21857294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of antiretroviral therapy in resource-poor settings: are outcomes comparable to those in the developed world?
    Lawn SD; Myer L; Wood R
    Clin Infect Dis; 2005 Dec; 41(11):1683-4; author reply 1684. PubMed ID: 16267745
    [No Abstract]   [Full Text] [Related]  

  • 23. Early initiation of antiretroviral therapy and universal HIV testing in sub-Saharan Africa: has WHO offered a milestone for HIV prevention?
    Menon S
    J Public Health Policy; 2010 Dec; 31(4):385-400. PubMed ID: 21119646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Option B+ for the prevention of mother-to-child transmission of HIV infection in developing countries: a review of published cost-effectiveness analyses.
    Karnon J; Orji N
    Health Policy Plan; 2016 Oct; 31(8):1133-41. PubMed ID: 27016949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV treatment and care systems: the way forward.
    Ross DA; South A; Weller I; Hakim J
    AIDS; 2012 Dec; 26 Suppl 2():S147-52. PubMed ID: 23303436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Public health. Global HIV/AIDS policy in transition.
    Bongaarts J; Over M
    Science; 2010 Jun; 328(5984):1359-60. PubMed ID: 20538936
    [No Abstract]   [Full Text] [Related]  

  • 28. Conditional economic incentives to improve HIV prevention and treatment in low-income and middle-income countries.
    Galárraga O; Sosa-Rubí SG
    Lancet HIV; 2019 Oct; 6(10):e705-e714. PubMed ID: 31578955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pattern, Determinants, and Impact of HIV Spending on Care and Treatment in 38 High-Burden Low- and Middle-Income Countries.
    Granich R; Gupta S; Montaner J; Williams B; Zuniga JM
    J Int Assoc Provid AIDS Care; 2016; 15(2):91-100. PubMed ID: 26715490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing HIV treatment programs.
    Bautista-Arredondo S; Martz TE; Wirtz VJ; Bertozzi SM
    Curr Opin HIV AIDS; 2010 May; 5(3):232-6. PubMed ID: 20539079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The economics of HIV/AIDS in low-income countries: the case for prevention.
    Canning D
    J Econ Perspect; 2006; 20(3):121-42. PubMed ID: 17176527
    [No Abstract]   [Full Text] [Related]  

  • 32. UN political declaration on HIV and AIDS: where to begin?
    Poku NK
    Lancet; 2016 Aug; 388(10046):743-4. PubMed ID: 27560262
    [No Abstract]   [Full Text] [Related]  

  • 33. Access to medicines: lessons from the HIV response.
    Vella S; Wilson D
    Lancet HIV; 2017 Apr; 4(4):e147-e149. PubMed ID: 28359443
    [No Abstract]   [Full Text] [Related]  

  • 34. Global AIDS conference finds the issue is cash.
    Cullinan K
    Bull World Health Organ; 2002; 80(9):761-2. PubMed ID: 12378299
    [No Abstract]   [Full Text] [Related]  

  • 35. AIDS: lessons learnt and myths dispelled.
    Piot P; Kazatchkine M; Dybul M; Lob-Levyt J
    Lancet; 2009 Jul; 374(9685):260-3. PubMed ID: 19303630
    [No Abstract]   [Full Text] [Related]  

  • 36. Antiretroviral therapy in countries with low health expenditure.
    Arya SC
    Lancet; 1998 May; 351(9113):1433-4. PubMed ID: 9593437
    [No Abstract]   [Full Text] [Related]  

  • 37. Bitter pill: the current state of antiretroviral care in selected nations around the globe.
    Weber AE; Alakawaf R; Montaner JS; O'Shaughnessy MV; Hogg RS
    AIDS; 1999 Dec; 13(17):2481-2. PubMed ID: 10597794
    [No Abstract]   [Full Text] [Related]  

  • 38. Access to HIV drugs: are we changing the two world paradigm?
    Lazzarini Z
    Conn J Int Law; 2002; 17(2):281-96. PubMed ID: 12688297
    [No Abstract]   [Full Text] [Related]  

  • 39. Affordable drugs for developing countries.
    Chong CY
    Hong Kong Med J; 2003 Apr; 9(2):148-9. PubMed ID: 12668831
    [No Abstract]   [Full Text] [Related]  

  • 40. [The cost of an HIV patient. Lack of funds for optimal treatment?].
    Stoll M; Schulte E; Claes C; Graf von der Schulenburg JM; Schmidt RE
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():72-7. PubMed ID: 11373789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.